Isolation of therapeutic antibodies against Pseudomonas aeruginosa
Isolation of Human Recombinant Therapeutic Monoclonal Anti-Pseudomonas Antibodies From B Lymphocytes of Patients Who Have Been Followed for Infection or Colonization With Pseudomonas Aeruginosa: a Prospective Monocentric Trial
This study is trying to find new antibodies from patients to help treat infections caused by the tough-to-treat bacteria Pseudomonas aeruginosa.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 30 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University Hospital, Grenoble Academic / other |
| Locations | 1 site (Grenoble) |
| Trial ID | NCT04335383 on ClinicalTrials.gov |
What this trial studies
This study aims to isolate and produce therapeutic monoclonal antibodies targeting Pseudomonas aeruginosa, a pathogenic bacterium known for its multi-antibiotic resistance, particularly in hospital settings. By focusing on patients with existing functional anti-Pseudomonas antibodies, the study seeks to develop an alternative treatment option for infections caused by antibiotic-resistant strains. The approach involves collecting blood samples from eligible patients at Grenoble University Hospital to identify and isolate these antibodies for potential therapeutic use.
Who should consider this trial
Good fit: Ideal candidates are patients with a weight of at least 32 kg who have serum containing functional anti-Pseudomonas antibodies and are receiving care at Grenoble University Hospital.
Not a fit: Patients who are legally protected, such as minors, pregnant or nursing women, or those hospitalized under duress, will not benefit from this study.
Why it matters
Potential benefit: If successful, this could provide a new treatment option for patients suffering from infections caused by antibiotic-resistant Pseudomonas aeruginosa.
How similar studies have performed: While the approach of using monoclonal antibodies is established, the specific application to Pseudomonas aeruginosa in this context is relatively novel and has not been extensively tested.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patient selected in the retrospective part of the study (patient with serum containing functional anti-Pseudomonas aeruginosa antibodies) * Patient with weight ≥ 32kg. * With a follow-up visit at Grenoble University Hospital with a blood sampling for its care * Having given its written no objection to participate in the prospective phase of this project Exclusion Criteria: * Legally protected patient (minor, pregnant or nursing woman, ward or ward curated, hospitalized under duress or deprived of liberty)
Where this trial is running
Grenoble
- Chu Grenoble Alpes — Grenoble, France (Recruiting)
Study contacts
- Principal investigator: Yvan CASPAR, Dr — University Hospital, Grenoble
- Study coordinator: Yvan CASPAR, Dr
- Email: ycaspar@chu-grenoble.fr
- Phone: +33 4 76 76 54 79
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.